<?xml version="1.0" encoding="UTF-8"?>
<p>A rare but severe autoimmune neuropathy, Guillain-Barré syndrome (GBS) is the most common type of acute flaccid paralysis (AFP) [
 <xref rid="pntd.0007622.ref001" ref-type="bibr">1</xref>]. Often preceded by infections such as 
 <italic>Campylobacter jejuni</italic>, about 25% of patients require mechanical ventilation [
 <xref rid="pntd.0007622.ref002" ref-type="bibr">2</xref>]. Prognosis varies greatly based on GBS type and urgent care availability [
 <xref rid="pntd.0007622.ref002" ref-type="bibr">2</xref>–
 <xref rid="pntd.0007622.ref005" ref-type="bibr">5</xref>]. Many patients report residual deficits, including pain, limited mobility, and fatigue, years after disease onset [
 <xref rid="pntd.0007622.ref004" ref-type="bibr">4</xref>, 
 <xref rid="pntd.0007622.ref006" ref-type="bibr">6</xref>–
 <xref rid="pntd.0007622.ref008" ref-type="bibr">8</xref>]. Mortality rates range from 3−7% [
 <xref rid="pntd.0007622.ref003" ref-type="bibr">3</xref>, 
 <xref rid="pntd.0007622.ref009" ref-type="bibr">9</xref>], although they can be higher in settings with limited access to intensive care [
 <xref rid="pntd.0007622.ref010" ref-type="bibr">10</xref>, 
 <xref rid="pntd.0007622.ref011" ref-type="bibr">11</xref>]. In 2008, the total annual cost of GBS in the U.S. alone was estimated at $1.7 billion (95% CI $1.6 to 1.9 billion) [
 <xref rid="pntd.0007622.ref012" ref-type="bibr">12</xref>].
</p>
